Skip to main content

Advertisement

Table 3 Comparison in bivariate analysis of potential risk factors influencing the risk of presenting with at least one flare during the first 6 months of follow up of patients with all data available

From: Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study

  No flare between M0 and M6 At least 1 flare between M0 and M6 p value
Number of patients 23 13 /
DECT MSU volume knees (cm3) 0.6 ± 1.2 1.1 ± 1.6 0.24
DECT MSU volume feet (cm3) 0.9 ± 0.8 2.1 ± 1.9 0.05
Serum urate change between M0 and M6 (mg/dL) 1.51 ± 2.03 1.50 ± 2.48 0.88
Number of joints with the US double contour sign at M0 (/6) 2.5 ± 0.9 2.9 ± 1.5 0.67
Declared number of flares over the past year 3 ± 4.4 4.2 ± 6.2 0.41
Ongoing flare prophylaxis at M6 11 (47.8%) 6 (46.2%) 1
Ongoing urate lowering therapy at M0 13 (56.5%) 6 (46.2%) 0.8
  1. M0 month 0, M6 month 6, US ultrasonography, DECT dual-energy computed tomography, MSU, monosodium urate